Hormonal replacement therapy in ovarian cancer survivors: A survey among Greek gynecologists

European Journal of Gynaecological Oncology

Volumn 32, Issue 5, 2011, Pages 538-541

  Vavilis, D ^a   Chatzigeorgiou, K ^a   Goulis, D ^a   Pantazis, K ^a   Papanicolaou, A ^a   Theodoridis, T D ^a   Tarlatzis, B C ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Estrogen therapy; Estrogen progestogen therapy; Hormone replacement therapy; Ovarian cancer survivors; Prescription attitude; Tibolone

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; GESTAGEN; PHYTOESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE;

ADULT; ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER SURVIVOR; CLINICAL PRACTICE; DRUG CHOICE; DRUG INDICATION; DRUG SAFETY; FEMALE; GREECE; HEALTH SURVEY; HORMONE SUBSTITUTION; HUMAN; MALE; MEDICAL SPECIALIST; MENOPAUSAL SYNDROME; NORMAL HUMAN; OVARY CANCER; PHYSICIAN ATTITUDE; PRESCRIPTION; QUESTIONNAIRE;

ANTINEOPLASTIC AGENTS, HORMONAL; ATTITUDE OF HEALTH PERSONNEL; DIPHOSPHONATES; ESTROGENS; FEMALE; GREECE; GYNECOLOGY; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; NORPREGNENES; OVARIAN NEOPLASMS; PHYTOESTROGENS; PRESCRIPTIONS; PROGESTINS; QUESTIONNAIRES;

EID: 81255157122     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Jemal A., Murray T., Ward E., Samuels A., Tivari R.C., Ghafoor A. et al.: "Cancer statistics, 2005". CA Cancer J. Clin., 2005, 55, 10. Erratum CA Cancer J. Clin., 2005, 55, 259.
2. Altekruse S.F., Kosary C.L., Krapcho M., Neyman N., Aminou R., Waldron W. et al. (eds.). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
3. Baltzer J., Meerpohl H.-G., Bahnsen J. (eds). : "Maligne ovarial-tumoren". In: Praxis der Frauenheilkunde. Bd. III. Praxis der gynäkologischen Onkologie. Stuttgart-New York, Georg Thieme Verlag, 1999, 77, 215.
4. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A. et al.: "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study". J. Clin. Oncol., 2003, 21, 3194.
5. Persson I., Yuen J., Bergkvist L., Schairer C.: "Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort". Int. J. Cancer, 1996, 67, 327.
6. Hopkins M.L., Fung Kee Fung M., Le T., Shorr R.: "Ovarian cancer patients and hormone replacement therapy: a systematic review". Gynecol. Oncol., 2004, 92, 827.
7. Chatzigeorgiou K., Agorastos T., Vavilis D.: "Basic biology and metastatic spread in epithelial ovarian cancer". In: Chatzigeorgiou K.N., Bontis J.N. (eds.) Peritoneal Carcinomatosis from Ovarian Cancer. New York, Nova Science Publishers, 2005, 43.
8. Mascarenhas C., Lambe M., Bellocco R., Bergfeldt K., Riman T., Persson I., Weiderpass E.: "Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival". Int. J. Cancer, 2006, 119, 2907.
9. Lee K.B., Lee J.M., Yoon J.H., Park C.Y.: "The safety of tibolone in epithelial ovarian cancer patients". Maturitas, 2006, 55, 156.
10. Eeles R.A., Tan S., Wiltshaw E., Fryatt I., A'Herrn R.P., Shepherd J.H. et al.: "Hormone replacement therapy and survival after surgery for ovarian cancer". BMJ, 1991, 302, 259.
11. Guidocci F., Daponte A.: "Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial". Cancer, 1999, 86, 1013.
12. Ursic-Vrscaj M., Bebar S., Zakelj M.P., Primic M.: "Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival". Menopause, 2001, 8, 70.
13. Palacios S., Farias M.L., Luebbert H., Gomez G., Yabur J.A., Quail D.C. et al.: "Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate". Am. J. Obstet. Gynecol., 2004, 191, 121.
14. Neven P., Goldstein S.R., Ciaccia A.V., Zhou L., Silfen S.L., Muram D.: "The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women". Gynecol. Oncol., 2002, 85, 388.
15. North American Menopause Society. Treatment of menopause associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause, 2004, 11, 1133
16. Gercel-Taylor C., Feitelson A.K., Taylor D.D.: "Inhibitory effect of genistein and daidzein on ovarian cancer cell growth". Anticancer Res., 2004, 24, 795.
17. Klein A., He X., Roche M., Mallett A., Duska L., Supko J.G., Seiden M.V.: "Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy". Gynecol. Oncol., 2006, 100, 205.